Curaleaf Holdings Inc T.CURA

Alternate Symbol(s): CURLF

Curaleaf Holdings, Inc. is an international provider of consumer cannabis products. The Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide selection and accessibility across the medical and adult use markets. It operates in approximately 17 states and owns and operates 147 dispensaries and 21 cultivation sites with a focus on states, including Arizona, Florida, Illinois, Massachusetts, New Jersey, New York and Pennsylvania. It cultivates, processes, markets and/or dispenses a range of permitted cannabis products across its operating markets, including flower and pre-rolls, dry-herb vaporizer cartridges, concentrates for vaporizing such as pre-filled vaporizer cartridges and disposable vaporizer pens, concentrates for dabbing, such as mints, topical balms and lotions, tinctures, lozenges, capsules and edibles. Through Curaleaf International Holdings Limited, it has a supply and distribution network throughout the European market.

TSX:CURA - Post by User

Curaleaf Holdings Inc > Big Pharma won’t be happy about marijuana

<< Previous

Bullboard Posts

Next >>

Comment by Zaphodon Apr 24, 2022 10:40am

87 Views

Post# 34627185

RE:Big Pharma won’t be happy about marijuana

What does any of this have to do with the company's inability to turn a profit in fact it's a loss per share increases a sales increase if they double sales it's gonna double losses

the only person investing in this stock smoked too much of the company's product

blackspade799 wrote:
Seventy-two U.S. senators accepted donations from the pharmaceutical industry ahead of the 2020 election. That number was 302 for the House. Combined, that’s more than two-thirds of Congress.

If that makes you sick to your stomach, you might want to sit down for this: More than 2,400 state legislators around the country cashed checks from drug lobbyists, including 82% of state lawmakers in California, which has a deep blue legislature. That’s on par with 84% of lawmakers in Louisiana, a state redder than Mississippi, in case you are tempted to see this as a partisan problem.

In 2021, the lobbying industry broke its overall record — eclipsing $3.7 billion — with experts pointing to Congress’ renewed effort to lower prescription costs as the primary driver behind the spike in pharma spending. Apparently, some people are happy with the status quo and are willing to fight for it.

https://www.latimes.com/opinion/story/2022-04-20/marijuana-recreational-use-drugmakers-lobbying